Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current controversies in prenatal diagnosis 2: Cell‐free DNA prenatal screening should be used to identify all chromosome abnormalities

1 Feb 2018

Abstract excerpt

Noninvasive prenatal testing (NIPT) using cell-free DNA (cfDNA) from maternal serum has been clinically available since 2011. This technology has revolutionized our ability to screen for the common aneuploidies trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. More recently, clinical laboratories have offered screening for other chromosome abnormalities including sex chromosome abnormalities and copy number...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics
Share to Tumors and Oncological Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29417608
DOI: 10.1002/pd.5216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current controversies in prenatal diagnosis 2: Cell‐free DNA prenatal screening should be used to identify all chromosome abnormalitiesPMID 29417608Read ↗

Noninvasive screening by cell‐free DNA for 22q11.2 deletion: Benefits, limitations, and challengesSemantic proximity Read ↗

Non-Invasive Prenatal Testing: Advances, Applications, and Limitations in Prenatal ScreeningSemantic proximity Read ↗

Non-invasive prenatal testing: use of cell-free fetal DNA in Down syndrome screeningSemantic proximity Read ↗

PREIMPLANTATION GENETIC TESTING: Non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disordersSemantic proximity Read ↗

Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women?Semantic proximity Read ↗

ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practiceSemantic proximity Read ↗

Cell-Free DNA Testing for Fetal Chromosomal Anomalies in clinical practice: Austrian-German-Swiss Recommendations for non-invasive prenatal tests (NIPT)Semantic proximity Read ↗

International Society for Prenatal Diagnosis Position Statement: cell free (cf) DNA screening for Down syndrome in multiple pregnanciesSemantic proximity Read ↗

Novel perspectives in fetal biomarker implementation for the noninvasive prenatal testingSemantic proximity Read ↗

Non-Invasive Prenatal Testing (NIPT): Reliability, Challenges, and Future DirectionsSemantic proximity Read ↗

Non-Invasive Prenatal Testing: Current Perspectives and Future ChallengesSemantic proximity Read ↗

Rare autosomal trisomies on non‐invasive prenatal testing: not as adverse as expectedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.